liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
Sahlgrens University Hospital, Sweden .
Rigshosp, Denmark .
Norwegian University of Science and Technology, Norway .
Skåne University Hospital, Sweden .
Show others and affiliations
2013 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 121, no 23, 4647-4654 p.Article in journal (Refereed) Published
Abstract [en]

The Nordic Myeloma Study Group conducted an open randomized trial to compare bortezomib as consolidation therapy given after high-dose therapy and autologous stem cell transplantation (ASCT) with no consolidation in bortezomib-naive patients with newly diagnosed multiple myeloma. Overall, 370 patients were centrally randomly assigned 3 months after ASCT to receive 20 doses of bortezomib given during 21 weeks or no consolidation. The hypothesis was that consolidation therapy would prolong progression-free survival (PFS). The PFS after randomization was 27 months for the bortezomib group compared with 20 months for the control group (P = .05). Fifty-one of 90 patients in the treatment group compared with 32 of 90 controls improved their response after randomization (P = .007). No difference in overall survival was seen. Fatigue was reported more commonly by the bortezomib-treated patients in self-reported quality-of-life (QOL) questionnaires, whereas no other major differences in QOL were recorded between the groups. Consolidation therapy seemed to be beneficial for patients not achieving at least a very good partial response (VGPR) but not for patients in the andgt;= VGPR category at randomization. Consolidation with bortezomib after ASCT in bortezomib-naive patients improves PFS without interfering with QOL. This trial was registered at as #NCT00417911.

Place, publisher, year, edition, pages
American Society of Hematology , 2013. Vol. 121, no 23, 4647-4654 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-96994DOI: 10.1182/blood-2012-11-464503ISI: 000321895700008OAI: diva2:644850

Funding Agencies|Johnson Johnson||Nordic Cancer Union||Boras foundation for cancer research||

Available from: 2013-09-02 Created: 2013-09-02 Last updated: 2013-09-02

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Ahlberg, Lucia
By organisation
OncologyFaculty of Health SciencesDepartment of Haematology
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 28 hits
ReferencesLink to record
Permanent link

Direct link